Doris Hendig, PhD
Postdoctoral Research Fellow
Institute of Laboratory and Transfusion Medicine of the Heart and Diabetes Center
North Rhine-Westphalia, Bad Oeynhausen, Germany
Dr. Hendig received her Ph.D. in biochemistry from the Bielefeld University, Germany, in 2008. She is currently working as postdoctoral research fellow at the Institute of Laboratory and Transfusion Medicine of the Heart and Diabetes Center North Rhine-Westphalia in Bad Oeynhausen, Germany.
Scientific research at the institute is mainly concerned with the pathobiochemistry of extracellular matrix, the molecular diagnostics and cellular pathophysiology of pseudoxanthoma elasticum and the development of molecular biological methods for the detection of bacteria and viruses relevant to transfusion and infection. The PXE research group in Bad Oeynhausen is analyzing PXE-causing sequence variations in the ABCC6 gene. Further projects on PXE include elucidation of the cellular pathophysiology of extracellular matrix alterations in PXE. Additional foci are the identification of secondary genetic risk factors and evaluation of biomarkers which are suitable for determination of disease status and progression.
Dr. Hendig´s major research interests are the pathogenesis of extracellular matrix perturbations leading to human disease. Injuries of extracellular matrix structures lead to an unregulated activation of synthesis and degradation of matrix proteins and finally result in currently untreatable fibrosis and extraosseous calcification. Therein, her primary research focuses on proteoglycans, which represent sugar-containing proteins and the key enzymes involved in their synthesis. Dr. Hendig´s other research topic deals with the regulation of biological calcification in connective tissues.
The results of Dr. Hendig´s work on PXE were distinguished by the American Association of Clinical Chemistry and the Vereinigung südwestdeutscher Dermatologen in 2005. Her research on PXE was funded by grants from the Foundation for Pathobiochemistry and Molecular Diagnostic of the German Society for Clinical Chemistry and Laboratory Medicine (2005-2007) from the Ruhr-Universität Bochum, Rectorate Program (2009-2011) and from the Deutsche Forschungsgemeinschaft (DFG, since 2010).
Areas of Interest
Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG. Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol. 2011 Oct;152(4):695-703.
Zarbock R, Hendig D, Szliska C, Kleesiek K, Götting C. Analysis of MMP2 promoter polymorphisms in patients with pseudoxanthoma elasticum. Clinica Chimica Acta. 2010 Oct;411(19-20):1487–90.
Issa PC, Finger RP, Götting C, Hendig D, Holz FG, Scholl HPN. Centrifugal Fundus Abnormalities in Pseudoxanthoma Elasticum. Ophthalmology. 2010 Jul;17(7):1406-14.
Zarbock R, Hendig D, Szliska C, Kleesiek K, Götting C. Vascular Endothelial Growth Factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. Hum Mol Genet. 2009 Sep;18(17):3344-51.
Diekmann U, Zarbock R, Hendig D, Szliska C, Kleesiek K, Götting C. Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients. J Mol Med (Berl). 2009 Oct;87(10):965-70.
Hendig D, Langmann T, Kocken S, Zarbock R, Szliska C, Schmitz G, Kleesiek K, Götting C. Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis. Lab Invest. 2008 Dec;88(12):1303-15.
Götting C, Hendig D, Zarbock R, Szliska C, Kleesiek K. Complement factor H variant p.Y402H in pseudoxanthoma elasticum patients. Genet Test. 2008 Sep;12(3):431-6.
Hendig D, Adam A, Zarbock R, Szliska C, Kleesiek K, Götting C. Elevated serum levels of intercellular adhesion molecule ICAM-1 in Pseudoxanthoma elasticum. Clin Chim Acta. 2008 Aug;394(1-2):54-8.
Hendig D, Zarbock R, Szliska C, Kleesiek K, Götting C. The local calcification inhibitor matrix Gla protein in pseudoxanthoma elasticum. Clin Biochem. 2008 Apr;41(6):407-12.
Zarbock R, Hendig D, Szliska C, Kleesiek K, Götting C. Pseudoxanthoma elasticum: genetic variations in antioxidant genes are risk factors for early disease onset. Clin Chem. 2007 Oct;53(10):1734-40.
Hendig D, Arndt M, Szliska C, Kleesiek K, Götting C. SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem. 2007 May;53(5):829-36. Free article at Journal Website
Schulz V, Hendig D, Henjakovic M, Szliska C, Kleesiek K, Götting C. Mutational analysis of the ABCC6 gene and the proximal ABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). Hum Mutat. 2006 Aug;27(8):831.
Hendig D, Schulz V, Arndt M, Szliska C, Kleesiek K, Götting C. Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem. 2006 Feb;52(2):227-34. Free article at Journal Website
Götting C, Hendig D, Adam A, Schön S, Schulz V, Szliska C, Kuhn J, Kleesiek K. Elevated xylosyltransferase I activities in pseudoxanthoma elasticum (PXE) patients as a marker of stimulated proteoglycan biosynthesis. J Mol Med. 2005 Dec;83(12):984-92. Free article at Journal Website
Schulz V, Hendig D, Schillinger M, Exner M, Domanovits H, Raith M, Szliska C, Kleesiek K, Gotting C. Analysis of sequence variations in the ABCC6 gene among patients with abdominal aortic aneurysm and pseudoxanthoma elasticum. J Vasc Res. 2005 Sep-Oct;42(5):424-32.
Schulz V, Hendig D, Szliska C, Götting C, Kleesiek K. Novel mutations in the ABCC6 gene of German patients with pseudoxanthoma elasticum. Hum Biol. 2005 Jun;77(3):367-84.